This case highlights the potential efficacy of combining anti-angiogenic agents with targeted therapies like EGFR TKIs in EGFR-mutated advanced lung cancer, as evidenced by the remarkable tumor cavitation observed with the aumolertinib and anlotinib combination. Here, EGFR is linked to lung carcinoma.